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Recent studies have offered a glimpse into the sophisticated mechanisms by which inflamma-
somes respond to danger and promote secretion of interleukin (IL)-1b and IL-18. Activation of cas-
pases 1 and 11 in canonical and noncanonical inflammasomes, respectively, also protects against
infection by triggering pyroptosis, a proinflammatory and lytic mode of cell death. The therapeutic
potential of inhibiting these proinflammatory caspases in infectious and autoimmune diseases is
raised by the successful deployment of anti-IL-1 therapies to control autoinflammatory diseases
associated with aberrant inflammasome signaling. This Review summarizes recent insights into
inflammasome biology and discusses the questions that remain in the field.Introduction
From the primitive lamprey to humans, vertebrates use innate
and adaptive immune systems to defend against pathogens
(Boehm et al., 2012). In mammals, the innate immune system
mounts the initial response to threats. Concomitantly, den-
dritic cells and other antigen-presenting cells (APCs) relay in-
formation about the harmful agent to B and T lymphocytes of
the adaptive immune system. Lymphocytes have diverse anti-
gen receptors, and clonal expansion of the cells that recognize
the foreign material culminates in its targeted removal (Koch
and Radtke, 2011). Antigen receptor gene rearrangements in
lymphocytes enable the adaptive immune system to recognize
seemingly any antigen, but innate immune cells detect patho-
gens with a fixed number of germline-encoded ‘‘pattern
recognition receptors’’ (PRRs) (Takeuchi and Akira, 2010).
PRRs detect unique microbial structures termed pathogen-
associated molecular patterns (PAMPs). Microbial nucleic
acids, bacterial secretion systems, and components of the
microbial cell wall are examples of the conserved microbial
factors that are sensed by PRRs. Damaged host cells can
also trigger PRRs by releasing danger-associated molecular
patterns (DAMPs) such as uric acid crystals, ATP, high-
mobility group box 1 (HMGB1), and the heat-shock proteins
hsp70 and hsp90.
PRRs can be subdivided into twomajor classes based on their
subcellular localization. Toll-like receptors (TLRs) and C-type
lectin receptors (CLRs) are transmembrane proteins found in
the plasma membrane and endosomes, where they can survey
PAMPs and DAMPs in the extracellular milieu. A second class
of PRRs resides in intracellular compartments and includes the
RIG-I-like receptor (RLR), the AIM2-like receptor (ALR), and the
nucleotide-binding domain and leucine-rich repeat-containing
(NLR) proteins (Takeuchi and Akira, 2010). We would add to
this second class of PRRs the proteins that sense cytosolicDNA and trigger the production of type I interferon (Paludan
and Bowie, 2013).
Many PRRs encountering PAMPs and DAMPs trigger
signaling cascades that promote gene transcription by nuclear
factor-kB (NF-kB), activator protein 1 (AP1), and interferon regu-
latory factors (IRFs). Target genes encode cytokines, interferons,
and other proinflammatory or microbicidal proteins (Takeuchi
and Akira, 2010). A subset of NLRs and ALRs triggers a distinct
defense mechanism. These proteins assemble cytosolic protein
complexes called inflammasomes to activate proinflammatory
caspases 1 and 11 (Kayagaki et al., 2011; Martinon et al.,
2002). Rapid conversion of procaspase zymogens into enzymat-
ically active proteases results in: (1) the production of proinflam-
matory IL-1b and IL-18 and (2) the death of the cell.
Here, we review recent progress in our understanding of in-
flammasome signaling, the consequences of aberrant inflamma-
some signaling in human disease, and the therapeutic potential
of inflammasome modulation in inflammatory diseases.
Canonical and Noncanonical Inflammasomes: Platforms
for Caspase-1 and -11 Activation
Canonical inflammasomes convert procaspase-1 into the cata-
lytically active enzyme, whereas an undefined noncanonical
inflammasome promotes activation of procaspase-11 (Figure 1).
Caspases 1 and 11 belong to a family of aspartate-specific
cysteine proteases conserved through evolution. Like caspases
8, 9, and 10, which initiate apoptotic cell death, caspases 1 and
11 have large prodomains that mediate interactions with other
proteins. Interaction motifs belonging to the ‘‘death domain’’ su-
perfamily bring the zymogens into the activating protein complex
(Lamkanfi and Dixit, 2012; Riedl and Salvesen, 2007). These
homotypic interaction domains typically consist of six or seven
antiparallel a helices, the relative orientation of which determines
their classification as a caspase activation and recruitmentCell 157, May 22, 2014 ª2014 Elsevier Inc. 1013
Figure 1. Composition of Canonical and Noncanonical In-
flammasomes
The murine NLRs Nlrp3, Nlrp1b, and Nlrc4 and the ALR member absent in
melanoma 2 (AIM2) assemble canonical inflammasomes that promote acti-
vation of the cysteine protease caspase-1. NLRs are characterized by the
combined presence of a NACHT domain and a variable number of LRRs. Most
NLRs further contain either a CARD or PYDmotif in their amino-terminus. AIM2
is composed of an amino-terminal PYD and a carboxy-terminal DNA-binding
HIN200 domain. Note that murine Nlrp1b lacks the amino-terminal PYD motif
found in human NLRP1 and is autocatalytically cleaved in its central FIIND
domain. Nlrp1b and Nlrc4 recruit caspase-1 via their CARD motifs. The
bipartite PYD-CARD adaptor protein ASC may stabilize these interactions and
is required for assembly of the AIM2 and Nlrp3 inflammasomes. A currently
unknown cytosolic LPS sensor mediates activation of caspase-11 in the
noncanonical inflammasome. CARD, caspase recruitment domain; FIIND,
domain with function to find; LRR, leucine-rich repeat; NACHT, nucleotide-
binding and oligomerization domain; NLR, Nod-like receptor; PYD, pyrin.domain (CARD), pyrin domain (PYD), death domain (DD), or
death effector domain (DED).
The structural rearrangements that occur when procaspases 1
and 11 are activated have not been characterized in detail, but
activation is thought to mirror the proximity-induced activation
of caspases 8 and 9 (Riedl and Salvesen, 2007). Activation of
caspase-9 within the ‘‘apoptosome’’ has several features in
common with activation of caspase-1 within canonical inflam-
masomes. First, the apoptosome and canonical inflammasomes
are large, cytosolic, multiprotein complexes that recruit and
promote the activation of a CARD-containing initiator caspase.
Second, each complex consumes ATP and may have a dou-
ble-ringed wheel structure with 7- or 8-fold symmetry (Duncan1014 Cell 157, May 22, 2014 ª2014 Elsevier Inc.et al., 2007; Faustin et al., 2007; Riedl and Salvesen, 2007). Third,
recruitment of procaspases 1 and 9 to their respective com-
plexes is sufficient for them to acquire enzymatic activity (Broz
et al., 2010a; Riedl and Salvesen, 2007; Van Opdenbosch
et al., 2014), although their maturation into heterotetramers by
autoprocessing may lock the proteases into an enzymatically
active state. Finally, the intracellular K+ concentration appears
to set the threshold for assembly of the apoptosome and several
inflammasomes (Arlehamn et al., 2010; Cain et al., 2001; Mun˜oz-
Planillo et al., 2013). It is possible that cellular stress or damage
associated with K+ efflux relieves a checkpoint safeguarding the
cell against unwarranted activation of these lethal caspases.
Caspases 1 and 11 in Immunity and Host Defense
Inflammasomes modulate host defense responses through the
production of eicosanoids (von Moltke et al., 2012) and other
mechanisms (Lamkanfi, 2011), but the induction of pyroptosis
and secretion of proinflammatory IL-1b and IL-18 are considered
the prominent outcomes of inflammasome signaling. Pyroptosis
is a nonhomeostatic and lyticmode of cell death that requires the
enzymatic activity of caspase-1 or -11 (Kayagaki et al., 2011).
Cells dying by pyroptosis exhibit cytoplasmic swelling and
rupture of the plasma membrane, features that are shared with
caspase-independent necroptotic cell death (Lamkanfi, 2011).
Themolecular events underlying these changes remain obscure,
but the application of sophisticated proteomic approaches may
illuminate these phenomena in the future. Despite such gaps in
our knowledge, pyroptosis has emerged as a key defense
against microbial infections (Aachoui et al., 2013; Case et al.,
2013; Casson et al., 2013; Kayagaki et al., 2011; Miao et al.,
2010a). It is thought to halt the replication of intracellular patho-
gens by eliminating infected immune cells while simultaneously
promoting destruction of surviving bacteria by exposing them
to circulating phagocytes and neutrophils. Moreover, pyroptosis
may influence adaptive immunity against the infectious agent by
releasing antigens into the extracellular milieu, with DAMPs such
as IL-1a and HMGB1 acting as potential adjuvants. Further char-
acterization of the in vivo roles of pyroptosis will depend on the
identification of markers that are specific for this type of cell
death. Biomarkersmay also unveil potential differences between
caspase-1- versus caspase-11-induced pyroptosis.
Caspases 1 and 11 both induce pyroptosis, but only caspase-
1 processes IL-1b and IL-18 (Figure 2). IL-1b is a pyrogenic cyto-
kine that also promotes adaptive T helper 1 (Th1), Th17, and
humoral immunity. IL-18 is important for IL-17 expression by
Th17 cells and may polarize T cells toward Th1 or Th2 profiles in
combination with other cytokines (Dinarello, 2009). Unlike most
cytokines, IL-1b and IL-18 are not secreted through the classical
endoplasmic reticulum-Golgi route but are produced as biolog-
ically inactive precursor proteins that are cleaved prior to their
secretion as bioactive cytokines (Lamkanfi, 2011). Pro-IL-18 is
expressed constitutively in macrophages, whereas expression
of pro-IL-1b is regulated by NF-kB-mediated transcription.
Although caspase-11 is required for macrophages to secrete
IL-1b and IL-18 after infection with Escherichia coli, Citrobacter
rodentium, or Vibrio cholerae, caspase-1 must be activated too
(Gurung et al., 2012; Kayagaki et al., 2011). In contrast, pyropto-
sis in response to these bacteria requires caspase-11, but not
Figure 2. Major Effector Mechanisms of the
Canonical and Noncanonical Inflamma-
somes
Assembly of the canonical inflammasome com-
plexes promotes the proximity-induced autoacti-
vation of caspase-1. Caspase-1 subsequently
converts its substrates proIL-1b and proIL-18 into
the secreted bioactive cytokines and triggers
pyroptosis through an unknown mechanism. A
hypothetical noncanonical inflammasome that is
activated in response to the detection of cyotosolic
LPS triggers activation of caspase-11 in macro-
phages infected with Escherichia coli, Citrobacter
rodentium, Vibrio cholera, and other Gram-nega-
tive bacteria that enter the cytosol. Caspase-11
mediates pyroptosis and extracellular release of
IL-1a andHMGB1directly and induces secretion of
mature IL-1b and IL-18 indirectly through engage-
ment of the canonical Nlrp3 inflammasome.caspase-1 (Figure 2). Further evidence of a unique role for cas-
pase-11 is provided by the resistance of caspase-11-deficient
mice, but not caspase-1-deficient mice, in a model of endotoxic
shock (Kayagaki et al., 2011; Wang et al., 1998). Like caspase-1
deficiency, combined loss of the caspase-1 substrates IL-1b and
IL-18 does not provide significant protection in this model of
endotoxic shock (Kayagaki et al., 2011; Lamkanfi et al., 2010).
Pyroptosis to excess might promote sepsis by inducing immu-
nosuppression while amplifying the inflammatory response. In
this regard, activation of caspase-1 and pyroptosis in quiescent
CD4+ T cells was recently proposed to underlie the immunosup-
pressive and chronic inflammatory condition of HIV-infected in-
dividuals (Doitsh et al., 2014).
Caspase-11 responds to most intracellular Gram-negative
bacteria (Broz et al., 2012; Case et al., 2013; Casson et al.,
2013; Gurung et al., 2012; Rathinam et al., 2012), with those
invading the cytosol being detected earlier than those remaining
in vacuoles (Aachoui et al., 2013). In contrast, Gram-positive
pathogens do not activate caspase-11 (Rathinam et al., 2012).
The explanation for these observations is that activation of cas-
pase-11 is triggered by acylated lipid A, a component of the LPS
found in many Gram-negative bacteria (Hagar et al., 2013; Kaya-
gaki et al., 2013). Of note, intracellular LPS or acylated lipid A
activated caspase-11 in macrophages lacking the LPS receptor
TLR4. Indeed, TLR4-deficient mice treated first with a TLR3
agonist to induce expression of caspase-11 were susceptible
to a lethal dose of LPS, whereas themajority of caspase-11-defi-
cient mice survived this regimen (Hagar et al., 2013; Kayagaki
et al., 2013). These observations argue that there is another
LPS receptor besides TLR4 whose role is to activate caspase-
11 upon binding to intracellular LPS. Identification of this recep-
tor and the substrates of the noncanonical inflammasome should
shed light on the roles of human caspases 4 and 5. These
caspases share highest sequence homology with mouse cas-
pase-11, but whether they represent true functional orthologs
will require further study.
Canonical Inflammasome Subtypes and Their Activation
Mechanisms
Although the composition of the noncanonical inflammasome re-
mains unknown, several canonical inflammasomes that activate
caspase-1 in response to endogenous and exogenous dangersignals have been characterized. Each is named after its NLR
or ALR protein scaffold (Lamkanfi and Dixit, 2012). Human
NLRP2, NLRP6, NLRP7, NLRP12, and the ALR protein IFI16
may assemble inflammasomes, but additional studies are
needed to understand their importance for caspase-1 activation.
In contrast, the role of ALR AIM2 and the NLRs NLRP1, NLRP3,
and NLRC4 in inflammasome signaling is firmly established
(Figure 1). In the following section, we discuss the activation
mechanisms of these inflammasomes in additional detail.
The Nlrp1a and Nlrp1b Inflammasomes
Humans have a single NLRP1 gene, whereas mice have Nlrp1a,
Nlrp1b, and Nlrp1c genes. An important difference between hu-
man NLRP1 and its murine orthologs is that the latter lack a PYD
motif at the N terminus (Boyden and Dietrich, 2006). Nlrp1b is
highly polymorphic between mouse strains. Macrophages from
129S1 mice produce functional Nlrp1b but lack mRNA expres-
sion of the other two isoforms (Boyden and Dietrich, 2006; Sas-
talla et al., 2013). In contrast, C57BL/6 mice express Nlrp1a and
Nlrp1c but have mutations in Nlrp1b that render the Nlrp1b pro-
tein nonfunctional. The role of Nlrp1c remains to be discovered,
but genetic data support a role in inflammasome signaling for
Nlrp1a and Nlrp1b.
Mice homozygous for an activating Q593P point mutation
in Nlrp1a succumb to a systemic neutrophilic inflammatory dis-
ease at 3–5 months of age (Masters et al., 2012). Neutrophilia
is caused by excessive IL-1b production and pyroptosis of
hematopoietic progenitor cells. The mice exhibit profound cyto-
penia after chemotherapy or infection with lymphocytic chorio-
meningitis virus (LCMV). Biochemical studies may clarify what
triggers Nlrp1a activation and why the Q593P mutation in its
function-to-find (FIIND) domain renders the protein constitutively
active.
The Nlrp1b inflammasome is an important defense mecha-
nism against Bacillus anthracis because defective activation of
the Nlrp1b inflammasome hampers host defense in mice in-
fected with live B. anthracis spores (Moayeri et al., 2010; Terra
et al., 2010).Nlrp1b is the key locus determining whether macro-
phages undergo pyroptosis in response to B. anthracis lethal
toxin (LeTx) (Boyden and Dietrich, 2006). Thus, macrophages
from Nlrp1b-deficient mice fail to activate caspase-1 and are
defective at IL-1b secretion and pyroptosis in response to
LeTx (Kovarova et al., 2012). Nlrp1b recruits caspase-1 directlyCell 157, May 22, 2014 ª2014 Elsevier Inc. 1015
Figure 3. Schematic Overview of Proposed Inflammasome Activation Mechanisms
The different inflammasomes recruit and activate caspase-1 in response to a variety of triggers. PAMPs, DAMPs, pore-forming toxins, crystals, and UV radiation
are thought to activate the Nlrp3 inflammasome by reducing intracellular K+ concentrations, by promoting cytosolic release of lysosomal cathepsins, by
relocating Nlrp3 to the mitochondrial outer membrane, and by inducing mitochondrial damage, which may be sensed by Nlrp3 via the production of ROS or the
cytosolic release of oxidized mitochondrial DNA and cardiolipin. The presence of Bacillus anthracis lethal toxin in the cytosol might be detected through the
cleavage of Nlrp1b. Cells exposed to bacteria expressing flagellin or a type III (T3SS) or IV (T4SS) secretion system indirectly activate the Nlrc4 inflammasome
through Naip proteins. Mouse Naip1 and human NAIP bind the T3SS needle, while mouse Naip2 detects the rod component of T3SS and T4SS. Finally, mouse
Naip5 and -6 detect bacterial flagellin in the cytosol. These bacterial factors also induce PKCd-mediated phosphorylation of Nlrc4 on Ser533, which is required
for activation of the Nlrc4 inflammasome. AIM2 is activated by the presence of dsDNA in the cytosol of cells infected with Francisella tularensis, Listeria
monocytogenes, and the DNA viruses cytomegalovirus and vaccinia virus.via its CARD motif, although the bipartite PYD-CARD adaptor
protein ASCmay stabilize these interactions. Indeed, ASC is crit-
ical for Nlrp1b-induced caspase-1 autoprocessing but dispens-
able for LeTx-induced pyroptosis and IL-1b secretion (Van
Opdenbosch et al., 2014).
LeTx is a two-component toxin in which the ‘‘protective anti-
gen’’ subunit provides the metalloprotease effector subunit
‘‘lethal factor’’ (LF) access to the cytosol. Initially, Nlrp1b was
assumed to just physically associate with cytosolic LF, but it
was then shown that LF metalloprotease activity was needed
for its recognition (Fink et al., 2008). Subsequent studies showed
that LeTx cleaves Nlrp1b close to its N terminus (Chavarrı´a-
Smith and Vance, 2013; Hellmich et al., 2012). How removal of
a short (4 kDa) peptide from the N terminus promotes inflamma-
some activation requires further analysis (Figure 3).
The Nlrc4 Inflammasome
Similar to Nlrp1b, Nlrc4 contains a CARD motif through which it
interacts with caspase-1, and this probably explains why ASC is
dispensable for Nlrc4-induced pyroptosis (Figure 1). Neverthe-
less, ASC may amplify Nlrc4 inflammasome activity because
it is critical for Nlrc4-induced caspase-1 autoprocessing and
secretion of mature IL-1b and IL-18 (Broz et al., 2010b;Mariatha-
san et al., 2004; Van Opdenbosch et al., 2014). Nlrc4 responds
to two critical components of pathogenic bacteria: flagellin,
the building block of their locomotion machinery, and proteins
from the type III and IV bacterial secretion systems that inject
virulence factors into the host cell (Amer et al., 2006; Franchi
et al., 2006; Miao et al., 2006; Miao et al., 2010b). Consequently,
the Nlrc4 inflammasome is a major component of host defense
against facultative intracellular pathogens such as Salmonella
Typhimurium, Shigella flexneri, Pseudomonas aeruginosa, Bur-
kholderia thailandensis, and Legionella pneumophila (Lamkanfi1016 Cell 157, May 22, 2014 ª2014 Elsevier Inc.and Dixit, 2012). Activation of Nlrc4 involves members of the
Naip subfamily of NLRs (Kofoed and Vance, 2011; Rayamajhi
et al., 2013; Yang et al., 2013; Zhao et al., 2011). Naip proteins
have BIR motifs at their N terminus, whereas most NLRs carry
a CARD or PYD motif (Lamkanfi and Dixit, 2012). The murine
Naip locus is highly polymorphic. C57BL/6J mice express four
Naip proteins: Naip1 binds to the needle of the type III secretion
system (Rayamajhi et al., 2013; Yang et al., 2013), Naip2 binds to
the basal rod component (Kofoed and Vance, 2011; Zhao et al.,
2011), and Naip5 and Naip6 recognize flagellin (Kofoed and
Vance, 2011; Zhao et al., 2011). Humans express only one
NAIP homolog, and it binds to the needle structure of the type
III secretion system (Yang et al., 2013; Zhao et al., 2011). Once
Naip proteins have bound their ligands, they may bind to Nlrc4
to promote activation of caspase-1. Posttranslational modifica-
tion of Nlrc4 also contributes to inflammasome activation,
with Ser533 in Nlrc4 being phosphorylated after infection with
S. Typhimurium (Qu et al., 2012). This phosphorylation site ap-
pears conserved through evolution because a mouse Nlrc4 trun-
cation mutant lacking its CARD and an internal peptide was
phosphorylated at Ser533 when it was expressed in insect cells
(Hu et al., 2013). In crystals, CARD-less Nlrc4 adopted a solenoid
shape in which the LRRs folded back onto the NACHT domain
(Hu et al., 2013). Further investigation of the relationship between
Naip detection of bacterial components and Nlrc4 phosphoryla-
tion may illuminate how this inflammasome is activated.
The Nlrp3 Inflammasome
The Nlrp3 inflammasome is assembled when the amino-terminal
PYD of Nlrp3 engages in homotypic interactions with the PYD
of ASC to recruit caspase-1. However, the mechanisms associ-
ated with activation of the Nlrp3 inflammasome continue to be
debated. This inflammasome is activated by bacterial, viral,
Figure 4. Priming and Activation Signals of
the Nlrp3 Inflammasome
Although the exact molecular mechanisms of
NLRP3 inflammasome assembly are incompletely
understood, it is well-established that Nlrp3 acti-
vation requires two signals. Binding of the TLR4
ligand LPS to its receptor provides the first signal
by triggering NF-kB-mediated upregulation of
Nlrp3 along with proIL-1b. Alternatively, TLR4may
provide signal 1 through an incompletely under-
stood pathway involving its adaptor molecules
MyD88, IRAK1, and IRAK4 without the need for
new protein synthesis. BRCC3-mediated K63-
deubiquitination of Nlrp3 is required for Nlrp3
inflammasome assembly and activation by extra-
cellular ATP and other Nlrp3-activating stimuli.
These agents provide a second signal in the form
of K+ efflux, cytosolic release of lysosomal
cathepsins, relocalization of Nlrp3 from the cytosol
to mitochondria, or cytosolic release of mito-
chondria-derived factors such as reactive oxygen
species (ROS), cardiolipin, and oxidized mito-
chondrial DNA (mtDNA).and fungal pathogens, pore-forming toxins, crystals, aggregates
such as b-amyloid, and DAMPs such as ATP and hyaluronan
(Lamkanfi and Dixit, 2012). It is generally agreed that detection
of such a diversity of agents cannot be direct. Instead, Nlrp3 is
thought to monitor some host-derived factor that is altered
by these agents. Several hypotheses for Nlrp3 activation have
been formulated. They can be summarized as follows: Nlrp3 is
activated by: (1) K+ efflux (Mun˜oz-Planillo et al., 2013), (2) trans-
location to mitochondria (Misawa et al., 2013; Subramanian
et al., 2013; Zhou et al., 2011), (3) the production ofmitochondrial
reactive oxygen species (Zhou et al., 2011), (4) the release of
mitochondrial DNA or the mitochondrial phospholipid cardiolipin
(Iyer et al., 2013; Nakahira et al., 2011; Shimada et al., 2012), and
(5) the cytosolic release of lysosomal cathepsins (Hornung et al.,
2008). A single unifying event has not emerged because some
of these events do not occur with all Nlrp3-activating agents,
or they are associated with multiple inflammasomes, or their
occurrence is contested (Bauernfeind et al., 2011; Mun˜oz-Pla-
nillo et al., 2013; Pe´trilli et al., 2007). There is disagreement too
as to whether PKR (Lu et al., 2012), TXNIP (Zhou et al., 2010),
and MAVS (Subramanian et al., 2013) have important roles in
the Nlrp3 pathway (Ermler et al., 2014; He et al., 2013; Masters
et al., 2010; Mun˜oz-Planillo et al., 2013).
What is clear is that activation of the Nlrp3 inflammasome re-
quires two signals (Figure 4). First, an NF-kB-activating stimulusCell 1is required for cells to express pro-IL-1b
and optimal Nlrp3 (Bauernfeind et al.,
2009). Actual assembly of the Nlrp3 in-
flammasome occurs when a second
signal is provided by an Nlrp3-acti-
vating agent (Lamkanfi and Dixit, 2012).
Although Nlrp3 induction certainly con-
tributes to inflammasome activation, brief
TLR stimulation that doesn’t increase the
amount of Nlrp3 is sufficient to prime the
pathway for activation by ATP (Juliana
et al., 2012; Schroder et al., 2012). Thisalternative signal 1 is provided by TLR4 and is relayed by its
adaptors MyD88, IRAK1, and IRAK4 independently of new pro-
tein synthesis (Fernandes-Alnemri et al., 2013; Juliana et al.,
2012; Lin et al., 2014). Intriguingly, Nlrp3 deubiquitination is
required for inflammasome assembly and activation (signal 2)
(Juliana et al., 2012; Lopez-Castejon et al., 2013; Py et al.,
2013). The K63-specific deubiquitinase BRCC3 was proposed
to remove ubiquitin chains from the Nlrp3 leucine-rich repeat
(LRR) motifs at this step (Py et al., 2013). Whether this triggers
Nlrp3 relocalization, induces conformational changes, or serves
other purposes that promote Nlrp3 inflammasome assembly is
not known. Also the identity of the E3 ubiquitin ligase that mod-
ifies Nlrp3 in the basal state is unclear.
The AIM2 Inflammasome
The ALR protein AIM2 assembles a canonical inflammasome
that recruits ASC to activate caspase-1. It does so when its
DNA-binding HIN200 domain detects DNA from intracellular
pathogens such as Francisella tularensis, cytomegalovirus, and
vaccinia virus (Alnemri, 2010; Kanneganti, 2010). Mice lacking
AIM2 or caspase-1 fail to clear infections with F. tularensis, the
causative agent of tularaemia, illustrating the critical role that
the AIM2 inflammasome plays in host defense against microbial
pathogens (Alnemri, 2010). In association with Nlrp3 and Nlrc4,
AIM2 also contributes to caspase-1 activation by Listeria mono-
cytogenes (Rathinam et al., 2010; Sauer et al., 2010; Wu et al.,57, May 22, 2014 ª2014 Elsevier Inc. 1017
2010). It was suggested that AIM2 may be linked to the pathol-
ogy of autoimmune disorders such as systemic lupus erythema-
tosus where DNA-autoantibodies are abundant (Zhang et al.,
2013). If proven true, the pathway becomes a candidate for tar-
geted therapies.
Of note, AIM2 inflammasome activation in macrophages co-
incides with the formation of a single large perinuclear aggre-
gate or ‘‘speck’’ (Jones et al., 2010). Specks are also seen
upon activation of the Nlrp1b, Nlrc4, and Nlrp3 inflammasomes
(Broz et al., 2010a; Broz et al., 2010b; Van Opdenbosch et al.,
2014). Speck formation is explained by the tendency of the
ASC PYD domain to polymerize into star-shaped, branched
filaments that serve as platforms for caspase-1 clustering (Cai
et al., 2014; Lu et al., 2014). AIM2 and Nlrp3 nucleate ASC
fibers through their PYD domains (Cai et al., 2014; Lu et al.,
2014). The CARD of Nlrc4 triggers formation of similar ASC
fibers, and again, the PYD of ASC is important (Cai et al.,
2014). Of note, however, speck formation is not an absolute
requirement for inflammasome activity because S. Typhimu-
rium activates caspase-1 and induces pyroptosis even in the
absence of ASC (Broz et al., 2010b; Van Opdenbosch et al.,
2014). Nlrp1b-induced pyroptosis and IL-1b secretion also
have been reported to occur in the absence of ASC (Van Op-
denbosch et al., 2014).
Therapeutic Potential of Inflammasome Modulation
Aberrant inflammasome signaling contributes to pathology in a
large number of infectious (Lamkanfi and Dixit, 2011) and auto-
immune diseases (Lamkanfi and Dixit, 2012; Strowig et al.,
2012). Recent work implicated inappropriate inflammasome
signaling in graft-versus-host disease (Jankovic et al., 2013),
type 2 diabetes (Jourdan et al., 2013; Masters et al., 2010),
obesity-induced asthma (Kim et al., 2014), and insulin resistance
(Stienstra et al., 2011; Vandanmagsar et al., 2011; Wen et al.,
2011). Moreover, the NLRP3 inflammasome is activated during
age-related macular degeneration (AMD) (Marneros, 2013;
Tarallo et al., 2012). The accumulation of drusen and retinal dam-
age in AMD is the leading cause of central vision loss in the
elderly. Nlrp3 inflammasome blockade augmented retinal dam-
age in an acute laser-induced wound-healing model (Doyle
et al., 2012), but chronic NLRP3-driven IL-1b production may
contribute to AMD-associated chorioretinal pathology in pa-
tients. This hypothesis is supported by studies demonstrating
that deletion of Nlrp3 and caspase-1 reduced AMD pathology
in two mouse models that resemble age-dependent aspects of
human AMD (Marneros, 2013; Tarallo et al., 2012).
Alzheimer’s disease is another age-related degenerative dis-
order that is exacerbated by NLRP3 inflammasome activity.
Fibrillar b-amyloid deposits engage the NLRP3 inflammasome
in cultured microglia and recruit activated microglia to b-amyloid
plaques in the brain in vivo (Halle et al., 2008). More recently,
deletion of Nlrp3 or caspase-1 was demonstrated to reduce
memory loss and the accumulation of chronic b-amyloid
deposits in transgenic mouse models of Alzheimer’s disease
(Heneka et al., 2013). In keeping with these observations, micro-
glia in the vicinity of b-amyloid plaques in either Alzheimer’s pa-
tients or mouse models of the disease were shown to express
more IL-1b (Kim and de Vellis, 2005; Simard et al., 2006). In addi-1018 Cell 157, May 22, 2014 ª2014 Elsevier Inc.tion, mice lacking IL-1 receptor antagonist (IL-1Ra) exhibited
more neuronal damage when exposed to exogenous b-amyloid
(Craft et al., 2005).
Anti-IL-1 therapies have proven successful in several of
the aforementioned ailments, including type 2 diabetes and juve-
nile rheumatoid arthritis (Dinarello et al., 2012; Larsen et al.,
2007). Clinical studies may establish the therapeutic validity
of inflammasome inhibition in additional inflammatory disorders
in the future. To highlight a number of possible therapeutic
approaches, we will elaborate on inflammasome blockade in
autoinflammatory syndromes, which are often associated with
mutations in inflammasome-related genes.
Inherited autoinflammatory diseases are characterized by
recurrent episodes of inflammation in the absence of high-titer
autoantibodies and antigen-specific T cells. These criteria differ-
entiate them from autoimmune disorders in which autoreactive
antibodies and lymphocytes play a central role in pathogenesis.
Several autoinflammatory disorders are caused by mutations in
genes mediating or modulating inflammasome activation. Well-
studied examples are the cryopyrin-associated periodic fever
syndromes (CAPS), which include familial cold autoinflammatory
syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic
infantile neurological cutaneous and articular syndrome/
neonatal onset multisystem inflammatory disease (CINCA/
NOMID) (Feldmann et al., 2002; Hoffman et al., 2001). These dis-
eases produce urticarial skin rashes and prolonged episodes of
fever, and a significant number of patients have gain-of-function
mutations in NLRP3 (Feldmann et al., 2002; Hoffman et al.,
2001). The CAPS-associated mutations probably produce
conformational changes in NLRP3 that render the protein consti-
tutively active, thereby causing persistent caspase-1 activation
and disproportionate production of IL-1b and IL-18 (Dowds
et al., 2004).
Inhibition of IL-1 signaling has proven remarkably beneficial
in CAPS patients (Ter Haar et al., 2013). Several other autoin-
flammatory disorders, including tumor necrosis factor recep-
tor-associated periodic syndrome (TRAPS), in which disease is
causally linked with mutations in TNF-R1, have also benefited
from anti-IL-1 therapy. In fact, TRAPS patients respond signifi-
cantly better to IL-1 inhibition than to TNF blockade (Ter Haar
et al., 2013). Anti-IL-1 molecules currently approved for these
syndromes include rilonacept (Hoffman et al., 2012), anakinra
(Goldbach-Mansky et al., 2006), and canakinumab (Kuem-
merle-Deschner et al., 2011). Anakinra is a non-glycosylated
human IL-1 receptor antagonist, and rilonacept contains the
ligand-binding domains of human IL-1 receptor (IL-1R1) and
IL-1 receptor accessory protein (IL-1RAcP) fused to the Fc
portion of a human immunoglobulin G1 (IgG1). The interaction
of anakinra and rilonacept with the IL-1 receptor prevents IL-
1a and IL-1b from binding to the IL-1 receptor and exerting their
biological functions. In contrast, canakinumab is a humanized
monoclonal antibody that neutralizes IL-1b in circulation and
does not interfere with binding of IL-1a to the IL-1 receptor.
Several other molecules targeting either IL-1b or IL-1R are
currently under development (Dinarello et al., 2012).
Despite their remarkable efficacy, anti-IL-1 therapies do not
resolve all CAPS-associated symptoms (Neven et al., 2010).
One possible explanation is that the caspase-1-dependent
cytokine IL-18 still promotes disease. In mice expressing CAPS-
associatedNlrp3mutations, IL-18was important early in disease
development, whereas the effects of IL-1 dominated at later
stages (Brydges et al., 2013). Of note, however, a number of
CAPS mice lacking both IL-18 and the IL-1 receptor still suc-
cumbed to disease, whereas caspase-1 deficiency provided
full protection. Therefore, other caspase-1-mediated pathways,
such as pyroptosis, may contribute to CAPS pathology. These
findings highlight the potential benefits of blocking the NLRP3
inflammasome directly over inhibiting its downstream cytokines.
It is possible that CAPS and other patients might benefit from
pharmacologic inhibitors of caspase-1 such as VX-765, which
is presently being tested in epilepsy. This compound prevented
IL-1b secretion from LPS-stimulated peripheral blood mononu-
clear cells of FCASpatients in vitro (Stacket al., 2005), suggesting
therapeutic potential in CAPS disease. Continued development
of this and other caspase-1 inhibitors could potentially offer
patients with autoinflammatory and related immune disorders
additional options for improving their quality of life.
Conclusion and Perspectives
This Review has provided a discussion of the key advances
that have been made in understanding the roles and activation
mechanisms of inflammasomes and illustrated their increasingly
appreciated roles in infectious, autoimmune, and autoinflamma-
tory diseases. The existence of a noncanonical inflammasome
that responds to intracellular LPS and Gram-negative bacteria
has been proposed, the importance of posttranslational modifi-
cations in the activation of Nlrc4 and Nlrp1b demonstrated, and
the contribution of pyroptosis in host defense against microbes
and its role in autoinflammation clarified. These recent develop-
ments have raised some fascinating new questions for the
field nonetheless. For instance, how does deubiquitination
modulate Nlrp3 activation, what is the identity of the LPS sensor
activating caspase-11, and how do caspases 1 and 11 trigger
pyroptosis?
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